In a filing, Rocket Pharmaceuticals Inc revealed its insider Militello John unloaded Company’s shares for reported $5139.0 on Apr 22 ’25. In the deal valued at $7.16 per share,718 shares were sold. As a result of this transaction, Militello John now holds 65,039 shares worth roughly $0.43 million.
Then, Militello John bought 718 shares, generating $5,140 in total proceeds.
Before that, Shah Gaurav bought 20,000 shares. Rocket Pharmaceuticals Inc shares valued at $101,600 were divested by the CEO at a price of $5.08 per share. As a result of the transaction, Shah Gaurav now holds 792,680 shares, worth roughly $5.24 million.
BMO Capital Markets initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on March 12, 2025; the price target was $50. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late December with a ‘”an Outperform”‘ rating. Jefferies began covering RCKT with “Buy” recommendation on December 18, 2024. Scotiabank started covering the stock on October 16, 2024. It rated RCKT as “a Sector outperform”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -5.50% to $6.61. Over the last five days, the stock has gained 4.83%. Rocket Pharmaceuticals Inc shares have fallen nearly -47.37% since the year began. Nevertheless, the stocks have fallen -71.65% over the past one year. While a 52-week high of $26.98 was reached on 01/02/25, a 52-week low of $4.55 was recorded on 04/09/25. SMA at 50 days reached $7.27, while 200 days put it at $13.30.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 6.19, which if violated will result in even more drops to 5.76. On the upside, there is a resistance level at 7.09. A further resistance level may holdings at 7.56. The Relative Strength Index (RSI) on the 14-day chart is 45.13, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.24%. Stochastics %K at 32.11% indicates the stock is a holding.
The most recent change occurred on April 02, 2024 when Goldman began covering the stock and recommended ‘”a Neutral”‘ rating along with a $39 price target.
